Sign inJoin waitlistJoin the waitlist

Jia Luo

Assistant Professor of Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · · ·

History

Mass General Brigham
Present

Medical Oncology
Memorial Sloan Kettering Cancer Center
2017–2020
Internal Medicine
Oregon Health & Science University
2014–2017
Stanford University School of Medicine
2010–2014

Research

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Oncotarget · 2014 · 356 citations
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Cancer Discovery · 2020 · Co-first of 15 authors · 307 citations
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
Nature Cancer · 2022 · Co-first of 22 authors · 298 citations

MH
Matthew Hellmann
13 papers
Pasi Jänne
12 papers
CF
Christopher French
11 papers
Lynette Sholl
11 papers
MK
Mark Kris
11 papers
Biagio Ricciuti
10 papers · 9 as a resident
Geoffrey Shapiro
10 papers
AS
Adam Schoenfeld
9 papers · 6 as a fellow
David Barbie
9 papers
JC
Jamie Chaft
9 papers
MA
Mark Awad
9 papers
KA
Kathryn Arbour
8 papers

Clinical trials

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Site PI · Recruiting · Phase 1, Phase 2
Tango Therapeutics, Inc.
2025–2027